Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +40.37%
#2 Bitway Bitway +24.69%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.60%
#4 Starpower Starpower +20.94%
#5 aelf aelf +17.84%
#6 Pons Pons +15.88%
#7 Venom Venom +14.34%
#8 Decred Decred +14.08%
#9 DAPPOS DAPPOS +12.84%
#10 Wibx Wibx +8.12%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Tvardi Therapeutics, Inc. Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

TVRD
Rangering i aksjer #30251
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages... Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Aksjekurs
$1.88
Sist synkronisert: 2026-08-18
Markedsverdi
$17.59M
Endring (1 dag)
0.81%
Endring (1 år)
-92.40%
Land
US
Handel Tvardi Therapeutics, Inc. (TVRD)

Kategori

Healthcare
Inntekter for Tvardi Therapeutics, Inc. (TVRD)
Inntekter i 2026 TTM: 0
Ifølge Tvardi Therapeutics, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Tvardi Therapeutics, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE